Risk factors for CMV infection within 100 days posttransplantation in patients with acute leukemia

Objective: To investigate the risk factors for cytomegalovirus (CMV) infection within 100 days and the relationship between early CMV infection and 1-year relapse for patients with acute leukemia following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: Three hundred fifty-nine patients with acute leukemia who received allo-HSCT at our center between January 2015 and January 2020 were retrospectively reviewed. Results: Of 359 patients, 48.19% (173) patients experienced CMV infection within 100 days posttransplantation. In univariate and multivariate logistic analysis, haploidentical-related donor (HRD) (P < 0.001; odds ratio [OR], 5.542; 95% confidence interval [CI], 3.186–9.639), and ratio of CD3+CD8+ cells in lymphocytes <14.825% (P < 0.001; OR, 3.005; 95% CI, 1.712–5.275) were identified as 2 independent risk factors. One-year relapse rate (RR) between the CMV infection group and the non-CMV infection group was not statistically significant (18.5% vs 19.9%, P = 0.688). When we divided the total cohort into AML, ALL, and MAL subgroups, there were no significant differences as well (P = 0.138; P = 0.588; P = 0.117; respectively). Conclusion: In conclusion, donor type (HRD) and the insufficient recovery of CD3+CD8+ cells were independent risk factors for CMV infection within 100 days posttransplantation in patients with acute leukemia. CMV infection within 100 days did not influence the incidence of relapse in 1 year for patients with acute leukemia.

[1]  J. Bourhis,et al.  Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study , 2020, Bone Marrow Transplantation.

[2]  H. Einsele,et al.  How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. , 2020, Blood.

[3]  P. Hari,et al.  Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Kok,et al.  New advances in the management of cytomegalovirus in allogeneic haemopoietic stem cell transplantation , 2020, Internal medicine journal.

[5]  H. Einsele,et al.  Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). , 2019, The Lancet. Infectious diseases.

[6]  S. Avdic,et al.  Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients , 2019, Front. Microbiol..

[7]  J. Kanda,et al.  Lymphocyte Area Under the Curve as a Predictive Factor for Viral Infection after Allogenic Hematopoietic Stem Cell Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  K. Komanduri,et al.  Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation. , 2019, Blood.

[9]  A. Barrett,et al.  Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  J. Kwekkeboom,et al.  Potential Beneficial Effects of Cytomegalovirus Infection after Transplantation , 2018, Front. Immunol..

[11]  A. Krawczyk,et al.  Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real time PCR. , 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[12]  K. Komanduri,et al.  Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation. , 2017, Hematology/oncology and stem cell therapy.

[13]  G. Carcelain,et al.  Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation , 2017, The Journal of infectious diseases.

[14]  V. Miller,et al.  Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  R. Chemaly,et al.  How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. , 2016, Blood.

[16]  Xiao-hui Zhang,et al.  Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation. , 2016, The Journal of infection.

[17]  J. Storek,et al.  Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin-Conditioned Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  M. Norkin,et al.  Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. , 2016, Blood.

[19]  C. Solano,et al.  Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients , 2016, Open forum infectious diseases.

[20]  J. Cheong,et al.  Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia , 2015, Annals of Hematology.

[21]  R. Porcher,et al.  Relationship between cytomegalovirus (CMV) reactivation, CMV‐driven immunity, overall immune recovery and graft‐versus‐leukaemia effect in children , 2014, British journal of haematology.

[22]  B. Sandmaier,et al.  CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. , 2013, Blood.

[23]  D. Baarle,et al.  γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia , 2013, Leukemia.

[24]  L. Lanier,et al.  Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. , 2012, Blood.

[25]  S. Schnittger,et al.  Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. , 2011, Blood.